Literature DB >> 20826961

Sugammadex--a short review and clinical recommendations for the cardiac anesthesiologist.

Thomas M Hemmerling1, Cedrick Zaouter, Goetz Geldner, Dirk Nauheimer.   

Abstract

This review outlines the basic pharmacodynamic and pharmacokinetic properties of sugammadex for the cardiac anesthesiologist. It describes the different clinical scenarios when sugammadex can be used during cardiac surgery and gives clinical recommendations. Sugammadex is a unique reversal drug that binds a chemical complex with rocuronium and vecuronium, by which the neuromuscular blockade is quickly reversed. It is free of any clinical side-effects and doses of 2 mg/kg or more reliably reverse neuromuscular blockade within 5-15 min, depending on the depth of the neuromuscular blockade. Doses below 2 mg/kg should be avoided at any time because of the inherent risk of recurarization. Sugammadex should not replace good clinical practice--titration of neuromuscular blocking drugs to clinical needs and objective monitoring of neuromuscular blockade in the operating room or intensive care unit. Neuromuscular transmission should be determined in all patients before sugammadex is considered and 5 min after its administration to ensure that extubation is performed with normal neuromuscular transmission.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826961     DOI: 10.4103/0971-9784.69052

Source DB:  PubMed          Journal:  Ann Card Anaesth        ISSN: 0971-9784


  12 in total

1.  Sugammadex: Efficacy and Practicality in the Dental Office.

Authors:  Stephen Goetz; Benjamin Pritts; Bryant Cornelius
Journal:  Anesth Prog       Date:  2018

2.  [Modified rapid sequence induction for Caesarian sections : case series on the use of rocuronium and sugammadex].

Authors:  D Nauheimer; C Kollath; G Geldner
Journal:  Anaesthesist       Date:  2012-08       Impact factor: 1.041

3.  Sugammadex Use in a Patient with Wolff-Parkinson-White (WPW) Syndrome.

Authors:  Sevtap Hekimoğlu Şahin; İlhan Öztekin; Aytuna Kuzucuoğlu; Ayça Aslanoğlu
Journal:  Balkan Med J       Date:  2015-07-01       Impact factor: 2.021

4.  Is it not the time to stop the use of Scoline (suxamethonium chloride) for rapid sequence intubation?

Authors:  Sangeet Narang
Journal:  Sultan Qaboos Univ Med J       Date:  2011-10-25

5.  Comparative Effectiveness of Calabadion and Sugammadex to Reverse Non-depolarizing Neuromuscular-blocking Agents.

Authors:  Friederike Haerter; Jeroen Cedric Peter Simons; Urs Foerster; Ingrid Moreno Duarte; Daniel Diaz-Gil; Shweta Ganapati; Katharina Eikermann-Haerter; Cenk Ayata; Ben Zhang; Manfred Blobner; Lyle Isaacs; Matthias Eikermann
Journal:  Anesthesiology       Date:  2015-12       Impact factor: 7.892

Review 6.  Sugammadex: A revolutionary drug in neuromuscular pharmacology.

Authors:  Kusha Nag; Dewan Roshan Singh; Akshaya N Shetti; Hemanth Kumar; T Sivashanmugam; S Parthasarathy
Journal:  Anesth Essays Res       Date:  2013 Sep-Dec

7.  Effects of sugammadex on the coronary circulation: direct effects on coronary vessels or hypersensitivity (Kounis syndrome)?

Authors:  Hong-Seuk Yang; Ha-Jung Kim; Wonuk Koh
Journal:  Korean J Anesthesiol       Date:  2017-04-06

8.  Rocuronium-sugammadex use for electroconvulsive therapy in a hemodialysis patient: a case report.

Authors:  Shigeaki Kurita; Katsuyuki Moriwaki; Kazuhisa Shiroyama; Mikako Sanuki; Yukari Toyota; Minoru Takebayashi
Journal:  JA Clin Rep       Date:  2016-10-10

9.  Reversal agents in anaesthesia and critical care.

Authors:  Nibedita Pani; Pradeep A Dongare; Rajeeb Kumar Mishra
Journal:  Indian J Anaesth       Date:  2015-10

Review 10.  Neuromuscular blockade management in the critically Ill patient.

Authors:  J Ross Renew; Robert Ratzlaff; Vivian Hernandez-Torres; Sorin J Brull; Richard C Prielipp
Journal:  J Intensive Care       Date:  2020-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.